3Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis[J]. Hepatology, 1981; 1(3): 43.
4Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: Is blinding necessary[J]? Control Clin Trials, 1996; 17(34): 1-12.
5Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials[J]. JAMA, 1995; 273(5): 408-412.
6Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M. Does quality of reports of randomized trials affect estimates of intervention efficacy reported in Meta-analyses[J]? Lancet,1998; 352(9128): 609-613.
7Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses[J]. Annals of Internal Medicine, 2001; 135(11) : 982-989.
8Perter J, Jenkins BP, Portmann A.L, Eddleston W.F, Roger Williams. Use of polyunsaturated phosphatidyl choline in HBsAg negative chronic active hepatitis: results of prospective double blind controlled trial[J]. Liver, 1982; 2(3): 77-81.
9Kordac V, Brodanova M, Marecek Z, Jirasek AP. Essentiale forte in the treatment of chronic active hepatitis[J]. Prakt Lek (Praha), 1985; 65(43): 834-837.
10Niederau C, Strohmeyer G, Heintges T, Peter K, Gopfert E (Leich Study Group). Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double blind, placebo controlled trial[J]. Hepato-Gastroenterology, 1998; 45(21): 797-804.
